Baseline Kidney Function and the Effects of Dapagliflozin On Health Status in Heart Failure in DEFINE-HF and PRESERVED-HF
Dapagliflozin led to early and clinically meaningful improvements in health status in HF patients, regardless of EF or baseline eGFR.
Authors
- Silvio E. Inzucchi
- Sheryl L. Windsor (ORCID: https://orcid.org/0000-0003-0909-4309)
- Andrew P. Ambrosy (ORCID: https://orcid.org/0000-0002-4563-1071)
- Barry A. Borlaug (ORCID: https://orcid.org/0000-0001-9375-0596)
- Andrew J. Sauer (ORCID: https://orcid.org/0000-0002-9268-2795)
- Mikhail Kosiborod (ORCID: https://orcid.org/0000-0002-3750-9789)
- Kavita Sharma (ORCID: https://orcid.org/0000-0002-4264-1717)
- Guillermo E. Umpierrez (ORCID: https://orcid.org/0000-0002-3252-5026)
- Darren K. McGuire (ORCID: https://orcid.org/0000-0002-6412-7989)
- Sanjiv J. Shah (ORCID: https://orcid.org/0000-0002-5655-8201)
- Mansoor Husain
- Dalane W Kitzman
- Shachi Patel
Institutions
- Northwestern University (US)
- Parkland Health & Hospital System (US)
- Mayo Clinic (US)
- Kaiser Permanente (US)
- Johns Hopkins University (US)
- Emory University (US)
- University of Toronto (CA)
- Johns Hopkins Medicine (US)
- Yale University (US)
- Ted Rogers Centre for Heart Research (CA)
- Kaiser Permanente San Francisco Medical Center (US)
- Saint Luke's Hospital (US)
- Wake Forest University (US)
- University of Missouri–Kansas City (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1002/ehf2.15184
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- AstraZeneca
- Saint Luke's Health System